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AbstractMast cell chymase is a chymotrypsin-like serine
proteinase primarily stored in secretory mast cell gran-
ules. Mast cell chymase has various eﬀects on angio-
tensin, metalloproteases, lipoproteins, procollagen,
neuropeptides and cytokines. Recent studies have dem-
onstrated that chymase inhibitors inhibit skin inﬂam-
mation. In this study we sought to determine the role of
mast cell chymase in atopic dermatitis (AD) in com-
parison with its role in psoriasis and normal skin. Skin
biopsy specimens were obtained from non-lesional and
lesional skin of patients with chronic AD and psoriasis
and from normal skin of non-atopic and non-psoriatic
controls. The number of mast cells containing chymase
was determined by immunohistochemistry using a
chymase-speciﬁc monoclonal antibody. A signiﬁcantly
(P<0.05) enhanced number of chymase-positive cells
was found in lesional AD skin as compared to normal
skin as well as to lesional and non-lesional skin of pa-
tients with psoriasis. A signiﬁcant (P<0.05) increase in
the number of chymase-positive cells was also found in
non-lesional AD skin in comparison to psoriasis. An
enhanced, albeit not statistically signiﬁcant diﬀerence
was noted in non-lesional AD skin as compared to
normal skin. In conclusion, these results suggest that
mast cell chymase may play an integral part in eliciting
and maintaining cutaneous inﬂammation in AD but not
in psoriasis. The increased proteinase activity of mast
cell chymase may also be involved in promoting a skin
barrier defect in AD, which subsequently enhances the
skin’s permeability to allergens and microbes and
thereby aggravates the eczema.
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Introduction
Atopic dermatitis (AD) is a chronic inﬂammatory skin
disease characterized by extreme pruritus, relapsing
eczematous skin lesions and a personal or family history
of atopic diseases. Besides genetic, environmental and
pharmacological factors, various immunological mech-
anisms involving both the innate and adaptive immune
systems are thought to be critical in the pathogenesis of
AD [1]. Mast cells are an important component of innate
immunity and increased numbers of these cells are
observed in chronic AD skin lesions [2]. Mast cell
chymase (MCC) is a chymotrypsin-like serine proteinase
which is typically stored together with other proteinases
such as tryptase in secretory mast cell granules. The
main eﬀects of MCC include processing of various
substances such as angiotensin, metalloproteases, lipo-
proteins, procollagen, neuropeptides and cytokines [3].
Whereas polymorphism in the MCC gene has been re-
ported to be associated with AD by Mao et al. [4], other
investigations have failed to conﬁrm this association [5,
6]. Nevertheless, chymase inhibitors have recently been
shown to inhibit skin inﬂammation and an important
role for MCC in inducing inﬂammatory skin responses
has also been indicated in animal models of AD [3]. In
order to further clarify the role of MCC in eliciting and
maintaining eczema, we investigated immunoreactivity
for chymase in non-lesional and lesional skin of patients
with AD in comparison to that in skin of psoriatic pa-
tients and non-atopic and non-psoriatic controls.
Materials and methods
A group of 19 Caucasian patients (ten females and nine
males, age range 20–52 years) with moderate to severe
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chronic AD were included in the study after providing
informed consent. AD was diagnosed according to the
criteria of Haniﬁn and Rajka [7]. Punch biopsy speci-
mens of diameter 5 mm were taken from chronic
eczematous skin lesions (n=8) in the large joint ﬂexures,
which typically showed signs of licheniﬁcation, some
hyperkeratosis, erythema and excoriations, and from
non-lesional skin (n=11) located about 10 cm from a
chronic eczematous skin lesion. In order to compare the
immunoreactivity for chymase with another inﬂamma-
tory skin disease, punch biopsy specimens were also
obtained from lesional (n=8) and non-lesional skin
(n=7) of patients with psoriasis. None of these patients
had received any systemic corticosteroids or applied
topical corticosteroids at the site of the biopsy specimens
for at least 3 weeks prior to the investigation. Further-
more, normal skin from non-atopic and non-psoriatic
subjects (n=11) and one patient with cutaneous mast-
ocytosis was taken as a control.
The material was snap-frozen with or without tissue-
embedding medium using isopentane precooled in liquid
nitrogen and stored at 70C. Immunostaining for
MCC was performed using the avidin-biotin-complex/
alkaline phosphatase (ABC/AP) method. Cryostat tissue
sections of thickness 6 lm were air-dried, ﬁxed in ace-
tone for 8 min and rehydrated in Tris-buﬀered saline
with 0.1% saponin. The sections were then incubated for
3 h with a monoclonal mouse anti-human MCC anti-
body (1.0 mg/ml, dilution 1:700, clone CCI; Serotec,
Oxford, UK). After washing, the sections were incu-
bated for 1 h with a rabbit antimouse antibody (E0413;
DakoCytomation, Glostrup, Denmark) and thereafter
with ABC/AP (K0376; DakoCytomation). Finally, all
sections were developed with fuchsin (K0624; DakoCy-
tomation) and counterstained with hematoxylin. Sub-
stitution of the primary antibody with isotype-matched
IgG and omission of the primary antibody were used as
negative controls. Skin sections from a patient with
cutaneous mastocytosis were also stained as a positive
control in order to validate the speciﬁcity of the staining.
The slides were analyzed under a Leitz Dialux 20EB
microscope by two independent investigators. In each
section, staining was assessed on 15–25 ﬁelds at ·400
magniﬁcation. Cells displaying a strong cytoplasmic
staining and a nucleus were counted. The cells were
evaluated using a 0.063 mm2 grid and the number of
positive cells (mean±SEM) per millimeter squared was
determined. Statistical analysis was performed using
the Mann-Whitney U test (with the Bonferroni cor-
rection). P values <0.05 were considered statistically
signiﬁcant.
Results
Quantiﬁcation and localization of MCC-positive cells
are shown in Figs. 1 and 2. A signiﬁcantly (P<0.05)
enhanced number of MCC-positive cells was found in
lesional AD skin (Fig. 1a) as compared to normal skin
from non-atopic and non-psoriatic subjects (Fig. 1c) and
compared to lesional and non-lesional skin of patients
with psoriasis (Fig. 1d, e). A statistically signiﬁcant
(P<0.05) increase in the number of MCC-positive mast
cells was also found in non-lesional AD skin (Fig. 1b) in
comparison to psoriatic skin. An enhanced, but not
signiﬁcant, increase in the number of MCC-positive
mast cells was noted in non-lesional AD skin as com-
pared to normal skin from non-atopic and non-psoriatic
subjects. Immunoreactivity for MCC was signiﬁcantly
decreased in non-lesional and lesional psoriatic skin as
compared to normal skin. In lesional AD skin immu-
noreactivity for MCC was mainly localized around the
superﬁcial dermal vascular plexus (Fig. 1g) and,
although less pronounced, along the dermoepidermal
junction zone (Fig. 1f).
Discussion
In this study immunoreactivity for MCC was analyzed
in skin from patients with chronic inﬂammatory skin
diseases, namely AD and psoriasis, and compared with
that in normal skin. The number of mast cells containing
chymase was signiﬁcantly increased in chronic skin le-
sions of patients with AD but not in psoriatic skin. A
tendency to an enhanced, albeit statistically not signiﬁ-
cant, number of mast cells containing chymase was also
seen in non-lesional AD skin. Using a diﬀerent enzyme-
histochemical method, Ja¨rvikallio et al. [8] had in fact
previously demonstrated a signiﬁcantly enhanced
expression of MCC in non-lesional AD skin as well as
acute/subacute AD lesions. The use of a more stringent
non-parametric statistical analysis in our study may
partly explain this diﬀerence.
The increased expression of MCC in AD provides an
explanation for some of the typical clinical features of
patients with AD such as facial pallor and the tendency
to develop severe chronic eczema on the face and hands.
Interestingly, Weber et al. have recently reported that
mast cell numbers in humans are markedly increased at
peripheral anatomical sites such as the face and the
distal parts of the extremities, particularly the hands and
feet [9]. Since MCC can convert angiotensin I to
angiotensin II [10], the vasoconstrictive property of this
peptide may at least partly explain the facial pallor
which is seen in up to 50–60% of AD patients.
Previous studies have demonstrated that MCC has a
range of important proinﬂammatory eﬀects [3]. Mizu-
tani et al. [11] have reported that MCC leads to a rapid
and speciﬁc conversion of precursor interleukin-1b
(IL-1b) to active IL-1. Furthermore, injection of chym-
ase has been shown to cause an inﬂammatory response
in the skin, which is inhibited by diﬀerent chymase
inhibitors [12]. Taking together the increased expression
of MCC in AD and the enhanced numbers of mast cells
in the hands and the face [9], one may speculate that
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MCC is particularly a critical factor in eliciting and
perpetuating eczema at these body sites in patients with
AD. Enhancement of MCC seems rather speciﬁc for the
type of inﬂammatory skin response found in AD, since
no increase in the number of mast cells containing
chymase was seen in psoriasis. Although the precise
reasons for these distinctions still remain to be eluci-
dated, a diﬀerent cytokine/chemokine milieu in these
two chronic inﬂammatory skin disorders may be
responsible for the increased number of mast cells con-
taining chymase in AD [13]. A previously reported in-
crease in the expression of proteinase inhibitors in
psoriasis provides an additional explanation [14]. Such
proteinase inhibitors lead to conformational changes of
chymase, which not only inhibit the activity of this
protein but may also inﬂuence the binding aﬃnity and
thereby the immunoreactivity of the monoclonal anti-
body (CC1) used for the detection of chymase in this
study.
Structural changes, including papillary dermal ﬁbro-
sis and epidermal hyperplasia are further features of
chronic AD [1]. Besides various cytokines MCC may
also play an important part in the induction of tissue
ﬁbrosis and matrix remodeling due to its known eﬀects
on activation of procollagenase and metalloproteases as
well as degradation of extracellular matrix proteins [3].
Furthermore, dry skin together with itch are often
initially involved in triggering AD. Indeed, previous re-
ports have shown that chymase is a possible candidate
for mediating mast cell-induced pruritus in AD [15].
Moreover, previous studies have suggested that chy-
Fig. 1 Immunoreactivity for MCC is markedly increased in AD.
Skin sections from lesional and non-lesional skin of patients with
AD and psoriasis and one non-atopic, non-psoriatic subject are
shown as representative examples. An increased number of mast
cells containing chymase was observed in the dermis of lesional (a)
and non-lesional (b) AD skin in comparison to the non-atopic,
non-psoriatic control (c) as well as lesional (d) and non-lesional (e)
psoriatic skin (ABC/AP method, original magniﬁcation ·100). In
lesional AD skin immunoreactivity for MCC was mainly localized
around the superﬁcial dermal vascular plexus (g) and, although less
pronounced, along the dermoepidermal junction zone (f) (ABC/AP
method, original magniﬁcation ·400)
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motrypsin-like proteinases can modify proteinase-acti-
vated receptors, which are present on keratinocytes and
are thought to be involved in epidermal growth and
repair processes [16, 17]. Although the precise eﬀects of
MCC on keratinocytes in AD still remain to be eluci-
dated, MCC may participate in the events leading to
skin barrier dysfunction and dry skin. Interestingly, re-
cent reports have demonstrated that Netherton syn-
drome, which is characterized by ichthyosis associated
with erythroderma, hair shaft defects and atopic features
are caused by a mutation in the gene (SPINK5) encod-
ing the serine proteinase inhibitor LEKT1 [18]. The lack
of LEKT1 is thought to result in increased protease
activity in the stratum corneum, accelerated degradation
of desmoglein-1, and ﬁnally increased desquamation of
corneocytes leading to hyperkeratosis. This may lead to
the reduced lipid content in the stratum corneum and/or
altered composition from incomplete lipid processing
[18]. Intriguingly, a signiﬁcantly decreased expression of
LEKT1 precursor has recently also been reported in AD
in comparison to psoriasis [13]. Thus, it is tempting to
speculate that increased amounts of proteinases like
MCC primarily lead to an epidermal defect that in-
creases the skin’s permeability to allergens and microbes
which subsequently aggravate the eczema.
In conclusion, the increased number of mast cells
containing chymase in AD points to a critical role for
chymase in initiating as well as maintaining eczema in
these patients. The precise pathophysiological relevance
of chymase in eliciting skin barrier dysfunction in AD
remains to be clariﬁed in future studies.
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